消化系统恶性肿瘤中泛素特异性蛋白酶的研究现状
摘要
病之一，寻找有效的治疗靶点显得尤为迫切。泛素特异性蛋白酶（ubiquitin-specific proteases,USPs）作为调控蛋白质稳定性
和功能的重要酶类，近年来在肿瘤研究中受到广泛关注。目前众多去泛素化酶中，USP 家族成员数目最多 , 结构最清楚。
这些酶通过上皮 - 间质转化、调控细胞周期及细胞凋亡、影响肿瘤免疫、药物耐受以及信号通路等途径，导致恶性肿瘤的
发生发展。目前，USP 抑制剂可靶向抑制肿瘤生长，在多种体外实验及动物模型中显现出有效性。本文将针对 USP 家族成
员在几种消化系统肿瘤中的作用，及 USP 抑制剂在消化系统肿瘤中的应用现状进行讨论。
关键词
全文:
PDF参考
[1] Suresh B, Lee J, Kim K S, et al. The Importance of
Ubiquitination and Deubiquitination in Cellular Reprogramming[J].
Stem Cells International, 2016, 2016: 6705927.
[2] 刘湘宁 , 杜佳泯 , 钱美佳 , 等 . 去泛素化酶小分子抑
制剂抗肿瘤作用研究 : 新进展和新思路 [J]. 药学学报 , 2022,
57(3): 547-556.
[3] Rock K L, Gramm C, Rothstein L, et al. Inhibitors of the
proteasome block the degradation of most cell proteins and the
generation of peptides presented on MHC class I molecules[J].
Cell, 1994, 78(5): 761-771.
[4] Dewson G, Eichhorn P J A, Komander D. Deubiquitinases
in cancer[J]. Nature Reviews. Cancer, 2023, 23(12): 842-862.
[5] Chen D, Ning Z, Chen H, et al. An integrative pan-cancer
analysis of biological and clinical impacts underlying ubiquitinspecific-processing proteases[J]. Oncogene, 2020, 39(3): 587-
602.
[6] 张思维 , 郑荣寿 , 孙可欣 , 等 . 2016 年中国恶性肿瘤
分地区发病和死亡估计：基于人群的肿瘤登记数据分析 [J].
中国肿瘤 , 2023, 32(5): 321-332.
[7] Zhou H Z, Li F, Cheng S T, et al. DDX17-regulated
alternative splicing that produced an oncogenic isoform of PXNAS1 to promote HCC metastasis[J]. Hepatology (Baltimore, Md.),
2022, 75(4): 847-865.
[8] Li T, Yan B, Ma Y, et al. Ubiquitin-specific protease 4
promotes hepatocellular carcinoma progression via cyclophilin A
stabilization and deubiquitination[J]. Cell Death & Disease, 2018,
9(2): 148.
[9] Engstrand J, Nilsson H, Strömberg C, et al. Colorectal
cancer liver metastases - a population-based study on incidence,
management and survival[J]. BMC cancer, 2018, 18(1): 78.
[10] Li X, Stevens P D, Yang H, et al. The deubiquitination
enzyme USP46 functions as a tumor suppressor by controlling
PHLPP-dependent attenuation of Akt signaling in colon cancer[J].
Oncogene, 2013, 32(4): 471-478.
[11] Huang J, Lok V, Ngai C H, et al. Worldwide Burden
of, Risk Factors for, and Trends in Pancreatic Cancer[J].
Gastroenterology, 2021, 160(3): 744-754.
[12] Chen L, Xu Z, Li Q, et al. USP28 facilitates pancreatic
cancer progression through activation of Wnt/β-catenin pathway
via stabilising FOXM1[J]. Cell Death & Disease, 2021, 12(10):
887.
[13] 梁红光 . ARRB2 调控 WTAP 表达促进结肠癌细胞
生长和迁移 [D]. 南方医科大学 , 2023.
[14] Li X, Yuan J, Song C, et al. Deubiquitinase USP39 and
E3 ligase TRIm26 balance the level of ZEB1 ubiquitination and
thereby determine the progression of hepatocellular carcinoma[J].
Cell Death and Differentiation, 2021, 28(8): 2315-2332.
[15] Wu L, Zhao N, Zhou Z, et al. PLAGL2 promotes the
proliferation and migration of gastric cancer cells via USP37-
mediated deubiquitination of Snail1[J]. Theranostics, 2021, 11(2):
700-714.
[16] Zhang T, Zheng J, Qiao L, et al. Deubiquitinase USP13
promotes the epithelial-mesenchymal transition and metastasis in
gastric cancer by maintaining Snail protein[J]. Pathology, Research
and Practice, 2022, 229: 153705.
[17] Keerthivasan S, Aghajani K, Dose M, et al. β-Catenin
promotes colitis and colon cancer through imprinting of
proinflammatory properties in T cells[J]. Science Translational
Medicine, 2014, 6(225): 225ra28.
[18] 朱少义 . N-cadherin 和 β-catenin 异常表达对细胞
粘附、增殖及经典 Wnt 信号通路的影响 [D]. 新乡医学院 ,
2019.
[19] Hua Y qiang, He Y, Ding X bo, et al. USP51, an
oncogene for pancreatic cancer (PC) cell growth via Wnt/
β-catenin pathway[M]. 2020.
[20] Wang X M, Yang C, Zhao Y, et al. The deubiquitinase
USP25 supports colonic inflammation and bacterial infection and
promotes colorectal cancer[J]. Nature Cancer, 2020, 1(8): 811-
825.
[21] Yan Y, Feng X, Li C, et al. Treatments for resectable
esophageal cancer: from traditional systemic therapy to
immunotherapy[J]. Chinese Medical Journal, 2022, 135(18):
2143-2156.
[22] Li B, Chan H L, Chen P. Immune Checkpoint Inhibitors:
Basics and Challenges[J]. Current Medicinal Chemistry, 2019,
26(17): 3009-3025.
[23] Wang Y, Sun Q, Mu N, et al. The deubiquitinase USP22
regulates PD-L1 degradation in human cancer cells[J]. Cell
communication and signaling: CCS, 2020, 18(1): 112.
[24] Huang X, Zhang Q, Lou Y, et al. USP22 Deubiquitinates
CD274 to Suppress Anticancer Immunity[J]. Cancer Immunology
Research, 2019, 7(10): 1580-1590.
[25] Yang Q, Zhao J, Chen D, et al. E3 ubiquitin ligases:
styles, structures and functions[J]. Molecular Biomedicine, 2021,
2(1): 23.
[26] Wu J, Liu C, Wang T, et al. Deubiquitinase inhibitor
PR-619 potentiates colon cancer immunotherapy by inducing
ferroptosis[J]. Immunology, 2023, 170(3): 439-451.
[27] Wang L, Li M, Sha B, et al. Inhibition of deubiquitination
by PR-619 induces apoptosis and autophagy via ubi-protein
aggregation-activated ER stress in oesophageal squamous cell
carcinoma[J]. Cell Proliferation, 2021, 54(1): e12919.
[28] Sun Y, Sha B, Huang W, et al. ML323, a USP1 inhibitor
triggers cell cycle arrest, apoptosis and autophagy in esophageal
squamous cell carcinoma cells[J]. Apoptosis: An International
Journal on Programmed Cell Death, 2022, 27(7-8): 545-560.
[29] Xu X, Li S, Cui X, et al. Inhibition of Ubiquitin Specific
Protease 1 Sensitizes Colorectal Cancer Cells to DNA-Damaging
Chemotherapeutics[J]. Frontiers in oncology, 2019, 9.
[30] Davis M I, Pragani R, Fox J T, et al. Small Molecule
Inhibition of the Ubiquitin-specific Protease USP2 Accelerates
cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal
Cancer and Mantle Cell Lymphoma Models[J]. The Journal of
Biological Chemistry, 2016, 291(47): 24628-24640.
[31] Wang Z, Kang W, Li O, et al. Abrogation of USP7 is an
alternative strategy to downregulate PD-L1 and sensitize gastric
cancer cells to T cells killing[J]. Acta Pharmaceutica Sinica. B,
2021, 11(3): 694-707.
[32] An T, Gong Y, Li X, et al. USP7 inhibitor P5091 inhibits
Wnt signaling and colorectal tumor growth[J]. Biochemical
Pharmacology, 2017, 131: 29-39.
[33] Zhang W, Zhang J, Xu C, et al. Ubiquitin-specific
protease 7 is a drug-able target that promotes hepatocellular
carcinoma and chemoresistance[J]. Cancer Cell International,
2020, 20: 28.
[34] Chen H, Zhu X, Sun R, et al. Ubiquitin-specific
protease 7 is a druggable target that is essential for pancreatic
cancer growth and chemoresistance[J]. Investigational New Drugs,
2020, 38(6): 1707-1716.
[35] Schauer N J, Liu X, Magin R S, et al. Selective USP7
inhibition elicits cancer cell killing through a p53-dependent
mechanism[J]. Scientific Reports, 2020, 10(1): 5324.
[36] Liu H, Chen W, Liang C, et al. WP1130 increases
doxorubicin sensitivity in hepatocellular carcinoma cells through
usp9x-dependent p53 degradation[J]. Cancer Letters, 2015,
361(2): 218-225.
[37] Ma T, Chen W, Zhi X, et al. USP9X inhibition improves
gemcitabine sensitivity in pancreatic cancer by inhibiting
autophagy[J]. Cancer Letters, 2018, 436: 129-138.
[38] Ding W, Wang J X, Wu J Z, et al. Targeting proteasomal
deubiquitinases USP14 and UCHL5 with b-AP15 reduces
5-fluorouracil resistance in colorectal cancer cells[J]. Acta
pharmacologica Sinica, 2023, 44(12).
[39] Ding Y, Chen X, Wang B, et al. Deubiquitinase inhibitor
b-AP15 activates endoplasmic reticulum (ER) stress and inhibits
Wnt/Notch1 signaling pathway leading to the reduction of cell
survival in hepatocellular carcinoma cells[J]. European Journal of
Pharmacology, 2018, 825: 10-18.
[40] Cheng C, Yao H, Li H, et al. Blockade of the
deubiquitinating enzyme USP48 degrades oncogenic HMGA2
and inhibits colorectal cancer invasion and metastasis[J]. Acta
Pharmaceutica Sinica. B, 2024, 14(4): 1624-1643.
[41] Wang X, Mazurkiewicz M, Hillert E K, et al. The
proteasome deubiquitinase inhibitor VLX1570 shows selectivity
for ubiquitin-specific protease-14 and induces apoptosis of
multiple myeloma cells[J]. Scientific Reports, 2016, 6: 26979.
[42] Yap T A, Lakhani N J, Patnaik A, et al. First-inhuman phase I trial of the oral first-in-class ubiquitin specific
peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single
agent (SA) and in combination with olaparib (OLA) or carboplatin
(CARBO) in patients (pts) with advanced solid tumors, enriched
for deleterious homologous recombination repair (HRR) mutations.
[J]. Journal of Clinical Oncology, 2024, 42(16_suppl): 3005-3005.
[43] 申香玉 , 史磊 , 申远 . 泛素特异性蛋白酶在肿瘤发
生发展中的作用 [J]. 生命的化学 , 2021, 41(4): 693-706.
(6 摘要 Views, 3 PDF Downloads)
Refbacks
- 当前没有refback。